Study of Mana 312 (Multi Tumor-Associated Antigen T Cells) in Adults With AML/MDS After HSCT
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04679194|
Recruitment Status : Active, not recruiting
First Posted : December 22, 2020
Last Update Posted : March 16, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|AML/MDS||Biological: Mana 312||Phase 1|
This is a Phase 1, open-label, non-randomized, single and multiple dose escalation study designed to evaluate the safety and preliminary efficacy (prevention of, or treatment of relapse) of administering Mana 312 to subjects with AML/MDS after allogeneic HSCT. The study will evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of single and multiple doses of Mana 312. Each cycle of administration of Mana 312 will be 28 days.
In the Escalation Cohorts, subjects with low, intermediate, and adverse/high risk of relapse will be enrolled using a modified 3+3 design. Upon completion of Cycle 1, subjects not experiencing dose-limiting toxicity (DLT) may continue receiving their assigned Mana 312 dose every 28 days for an additional 2 doses unless the subject experiences progressive disease (PD), exhausts their supply of Mana 312, experiences intolerable side effects, is removed by the Investigator, withdraws consent, or the study is terminated. After Cohort 1 has been completed (i.e., a decision has been made to proceed to Cohort 2), enrollment will be limited to subjects with high-risk of relapse AML/MDS (see Inclusion Criterion #4b) until the RP2D is determined).
In the Expansion Cohort, only subjects with high risk of relapse AML/MDS will be enrolled using the RP2D of Mana 312. Subjects in the Expansion Cohort will receive Mana 312 at the time of relapse or at 1 year after HSCT, whichever is first. Subjects not experiencing dose-limiting toxicity (DLT) may continue receiving their assigned Mana 312 dose every 28 days for an additional 2 doses unless the subject experiences progressive disease (PD), exhausts their supply of Mana 312, experiences intolerable side effects, or the study is terminated.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||27 participants|
|Intervention Model:||Sequential Assignment|
|Masking:||None (Open Label)|
|Official Title:||Ph 1 Study of Escalating Single & Multiple Doses of Mana 312 (Multi Tumor-Associated Antigen T Cells) Administered to Adult Subjects With Acute Myeloid Leukemia or Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplant|
|Actual Study Start Date :||December 8, 2020|
|Estimated Primary Completion Date :||March 2023|
|Estimated Study Completion Date :||March 2023|
Experimental: Mana 312
Mana 312 is administered intravenously (IV) within 30 minutes in either an inpatient or outpatient setting; either a central or peripheral IV line may be used. Each cycle of administration of Mana 312 will be 28 days.
Subjects not experiencing dose-limiting toxicity (DLT) following their initial dose may continue receiving their assigned Mana 312 dose every 28 days for an additional 2 doses
Biological: Mana 312
Mana 312 is a cellular product comprised of expanded T cells derived from allogeneic donor leukocytes that have been stimulated with monocyte derived dendritic cells pulsed with tumor-associated antigen (TAA) peptide mixes for 3 antigens: Wilms Tumor gene 1 (WT 1), the preferentially expressed antigen of melanoma (PRAME), and Survivin.
Each Mana 312 product is specifically matched for an individual subject and will be manufactured from leukocytes from the same donor who provided stem cells to that subject for their current allogeneic hematopoietic stem cell transplantation (HSCT).
- Escalation Cohorts: Identify the Maximum Tolerated Dose (MTD) of Mana 312 based on the safety and tolerability of single and multiple doses. [ Time Frame: 6 months ]Maximum Tolerated Dose
- Escalation Cohorts: Identify the Recommended Phase 2 Dose (RP2D) of Mana 312 based on the safety and tolerability of single and multiple doses. [ Time Frame: 6 months ]Recommended Phase 2 Dose
- Expansion Cohort: Assess preliminary antitumor efficacy of Mana 312 by CR. [ Time Frame: 1 year ]CR Rate
- Expansion Cohort: Assess preliminary antitumor efficacy of Mana 312 by PFS. [ Time Frame: 1 year ]PFS Rate
- Escalation Cohorts: Assess preliminary evidence of Mana 312 antitumor efficacy by CR. [ Time Frame: 1 year ]CR Rate
- Escalation Cohorts: Assess preliminary evidence of Mana 312 antitumor efficacy by PFS. [ Time Frame: 1 year ]PFS Rate
- Expansion Cohort: Confirm safety of the RP2D by measurement of TEAEs. [ Time Frame: 6 months ]Assess number of Treatment Related Adverse Events
- Characterize the pharmacokinetics (PK) by measurement of Mana 312 cell counts [ Time Frame: 6 months ]Determine Mana 312 cell counts
- Characterize the pharmacokinetics (PK) by measurement of antidrug antibodies (ADAs) [ Time Frame: 6 months ]Measure presence or absence of antidrug antibodies to Mana 312
- Characterize the anti-drug antibody (ADA) response to Mana 312. [ Time Frame: 6 months ]Detect presence or absence of neutralizing antibodies to Mana 312
- Determine Area Under the Curve (AUC) Pharmacokinetics of Mana 312 [ Time Frame: 6 months ]AUC
- Measure the Maximum Concentration Pharmacokinetics of Mana 312 [ Time Frame: 6 months ]Cmax
- Measure blast cell antigen expression pharmacodynamic markers of Mana 312 [ Time Frame: 1 year ]Measure expression of three target antigens
- Assess potential cytokine induction pharmacodynamic markers of Mana 312 [ Time Frame: 1 year ]Assess potential cytokine induction as potential biomarker of pharmacodynamic activity
- Measure cell expansion pharmacodynamic markers of Mana 312 [ Time Frame: 1 year ]Measure cell expansion persistence of Mana 312 subclones
- Measure immune subset pharmacodynamic markers of Mana 312. [ Time Frame: 1 year ]Measure immune subset changes by flow cytometry
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
Select Inclusion Criteria:
- Subject is ≥18 years of age on the day Informed Consent is signed and dated.
- Subject must have received only one allogeneic HSCT from a related or unrelated donor prior to administration of Mana 312.
- Subject has a donor who has agreed to donate leukocytes for manufacture of Mana 312 and who is the same donor who provided cells for the subject's current HSCT.
- a. Prior to HSCT, for Escalation Cohort 1, subject has AML/MDS b. Prior to HSCT, for Escalation Cohorts after Cohort 1 and for the Expansion Cohort, a subject must have high risk of relapse AML/MDS
Mana 312 product is available
The following Inclusion Criteria apply only during the Pre-Infusion Screening Phase, prior to the time of the planned first infusion of Mana 312.
- Subject has Eastern Cooperative Oncology Group (ECOG) performance status ≤ 3 or Karnofsky/Lansky score of ≥ 50.
- Subjects in the Expansion Cohort must have a relapse of AML/MDS (MRD+ or morphologic relapse)
- Subject has adequate organ function
Select Exclusion Criteria:
- Subject has received antibody that affects T-cell number or function
- Subject has received a donor lymphocyte infusion (DLI) for the current HSCT.
- Evidence of GVHD ≥ Grade 2 in any organ system, or active bronchiolitis obliterans syndrome, sclerotic GVHD, or symptomatic serositis.
- Subject has undergone major surgery (excluding minor procedures, eg, placement of vascular access, gastrointestinal/biliary stent, apheresis, or biopsy) < 21 days prior to the first planned infusion of Mana 312.
- Subject has an active and clinically relevant infection
- Subject has symptomatic or uncontrolled brain metastases, leptomeningeal disease, or spinal cord compression (radiation therapy to local site for disease control is allowed if ≥ 14 days prior to Screening and all AE from radiation therapy have resolved to ≤ Grade 1 prior to the planned first Mana 312 infusion).
- Subject has any other medical condition not listed above or social condition that, in the opinion of the Investigator, might place the subject at increased risk, adversely affect compliance, or confound safety or other clinical study data interpretation.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04679194
|United States, Colorado|
|Colorado Blood Cancer Institute|
|Denver, Colorado, United States, 80218|
|United States, Georgia|
|Northside Hospital - Atlanta|
|Atlanta, Georgia, United States, 30309|
|United States, Kansas|
|University of Kansas Cancer Center|
|Kansas City, Kansas, United States, 66103|
|United States, New York|
|Memorial Sloan Kettering Cancer Center|
|New York, New York, United States, 10065|
|United States, Tennessee|
|Nashville, Tennessee, United States, 37203|
|Vanderbilt - Ingram Cancer Center|
|Nashville, Tennessee, United States, 37232|
|United States, Texas|
|Texas Transplant/St David's South Austin|
|Austin, Texas, United States, 78704|
|Texas Transplant/Methodist Hospital|
|San Antonio, Texas, United States, 78229|
|Principal Investigator:||Lou Vaickus, MD||Mana Therapeutics Interim Chief Medical Officer|
|Responsible Party:||Mana Therapeutics|
|Other Study ID Numbers:||
|First Posted:||December 22, 2020 Key Record Dates|
|Last Update Posted:||March 16, 2023|
|Last Verified:||March 2023|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|